Difficult Cases in Breast Cancer - 2020 Annual Meeting
It is imperative that radiation oncologists remain current in state of the art clinical trials, and moreover that they understand how to utilize this data to provide appropriate patient care. This difficult cases panel will allow participants a window into how the expert panel uses modern data and clinical experience to guide clinical decision-making.
The activity is designed to meet the interests of radiation oncologists, nurses, and radiation oncology residents.
- Identify the appropriate indications for hypofractionation, and be ready to integrate this into their practice.
- Describe the controversies surrounding management of the axilla, and be able to utilize this knowledge to appropriately council patients and make treatment decisions.
- Jennifer Bellon, MD, FASTRO is employed at Brigham and Women's Hospital, receives compensation from Leidos Pharaceutical, Varian, and Wolters Kluwer. Dr. Bellon has a research grant from Prosigna.
- Julie Wong, MD is employed at Brigham and Women's Hospital and has no financial relationships with a commercial interest.
- Catherine Park, MD, FASTRO is employed at UCSF, has investment interest from Oncosynergy and Merck. Dr. Park has family who has investment interest from Telotherapeutics, Inc.
- Barbara Smith, MD is employed at Massachusetts General Hospital and has no financial relationships with a commercial interest.
- Benjamin Smith, MD, FASTRO is employed at UT MD Anderson Cancer Center and has family employed at UT MD Anderson Cancer Center. Dr. Smith has Patent/License Fees/Copyright: Royalty from Oncora Medical.
- Sara Tolaney is employed at Dana Farber Cancer Institute and has research grants from AstraZeneca, Bristol-Meyers Squbb, Cyclacel, Eisai, Eli Lilly, Exelixis, Genentech, Immunomedics, Merck, Nektar, Novartis, Odenate, Pfzier, Sanofi. Dr. Tolaney has investment interest from Abbvie, AstraZeneca, Athenex, Bristol-Meyers Squibb, Celldex, Daiichi-Sankyo, Eisai, Eli Lily, Genentech, Immunomedics, Merck, Nanostring, Nektar, Novartis, Paxman, Pfizer, Puma, Sanofi, Seattle Genetics.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.